Núria Pedreño López

Dr. Núria Pedreño Lopez graduated in Microbiology at the Autonomous University of Barcelona in 2013. In 2014, she obtained a Master's degree in Virology from Complutense University of Madrid, and moved to Miami (Florida, United States) to join the Watkins laboratory at the University of Miami. She worked as a technician for two years, and then joined as a graduate student. In 2020, she obtained her Ph.D. in Biochemistry and Molecular Biology under Dr. David Watkins supervision. Her dissertation was entitled “Isolation of novel anti-SIV monoclonal antibodies from rhesus macaques”. Dr. Pedreño Lopez then conducted postdoctoral studies in Washington (District of Columba, United States) in which she focused on the effect of non-neutralizing antibodies on suppressing SIVmac239 viremia in Indian rhesus macaques. Additionally, she became part of Mabloc LLC, a biotechnology startup company that developed monoclonal antibodies for the treatment and prevention of infectious disease (i.e. yellow fever, Zika, dengue viruses, as well as SARS-CoV-2).

Dr. Pedreño joined IrsiCaixa in 2021. At the Immunology group (IgG), which is directed by Dr. Jorge Carrillo, she studies the mechanism that causes COVID-19 illness.